GlassScriptPhysician profile
Kenneth Michael Towe
NPI 1417985078
$9,358.38
in general payments reported to CMS, 2019-2025
25 companies · $690 in 2025
The $690 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,762 · 2020: $62.66 · 2021: $394 · 2022: $591 · 2023: $1,101 · 2024: $758 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,549.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $3,569.84 | 2019 | |
| Abbott Laboratories | $1,577.96 | 2019-2025 | Jot Dx, Aveir, Gallant |
| Penumbra, INC. | $1,386.57 | 2019 | |
| Cvrx, INC. | $436.73 | 2022-2025 | Barostim Neo System |
| Amgen INC. | $354.24 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $320.29 | 2022-2025 | Symplicity G3 |
| Abiomed | $312.35 | 2024 | Impella |
| Janssen Pharmaceuticals, INC | $312.10 | 2019-2022 | |
| Boston Scientific Corporation | $207.72 | 2021-2023 | Guidezilla |
| Kestra Medical Technology Services, INC. | $142.28 | 2023 | Assure Wcd |
| Teleflex LLC | $115.61 | 2022 | |
| Biotronik INC. | $98.26 | 2023 | Recross, Orsiro Mission |
| Philips North America LLC | $97.02 | 2019-2023 | |
| Astellas Pharma US INC | $95.61 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $82.50 | 2019-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acist Medical Systems, INC. | $59.10 | 2019 | |
| Pfizer INC. | $37.07 | 2022-2023 | |
| Terumo Medical Corporation | $25.55 | 2024 | Tr Band, Angio-Seal |
| Azurity Pharmaceuticals, INC. | $23.72 | 2024 | Edarbi |
| Irhythm Technologies, INC. | $23.13 | 2019 | |
| Agepha Pharma Fz LLC | $19.72 | 2025 | Lodoco |
| E.R. Squibb & Sons, L.L.C. | $18.80 | 2024 | Eliquis |
| Chiesi USA, INC. | $18.77 | 2023 | Kengreal |
| Astrazeneca Pharmaceuticals LP | $17.33 | 2024 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6.11 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Towe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.